NASDAQHealth CareBiotechnologySnapshot 2026-07-23
Reading INSM? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This is a speculative growth investment. INSM is focused on expanding its revenue from existing products while advancing clinical trials, which adds potential but also carries inherent risks.
The market currently reflects a justified valuation, with a low expectations gap. However, INSM trades at a premium compared to its peers, indicating that some growth is already anticipated.
Management is on track to achieve significant revenue targets for BRINSUPRI and ARIKAYCE, which could support future growth. However, the company remains loss-making, and there is elevated risk due to recent litigation and the overall industry environment.
The thesis hinges on the performance of sector bellwethers like VRTX, REGN, and ARGX, as their results could influence INSM's trajectory. Additionally, management's ability to maintain guidance and avoid negative surprises will be crucial.
Overall, INSM's multi-year view remains intact, driven by strong management priorities and sector support. Not investment advice.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-07-23
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: Earnings results can change how investors feel. They also show trends in revenue.
Confirms one read:Earnings were better than expected. There is good guidance for future quarters.
Confirms the other:Earnings were worse than expected. Management has lowered guidance for the future.
Why it matters: Hitting this revenue target would confirm strong market demand and successful product launch. It is a key growth goal for Insmed.
Confirms:BRINSUPRI made at least $250 million in revenue in Q2 2026. This shows strong growth.
Disproves:BRINSUPRI revenue is below $200 million in Q2 2026. This suggests weaker demand.
Why it matters: Keeping this revenue range shows steady demand. It also shows a good market strategy for ARIKAYCE.
Confirms:ARIKAYCE revenue reported at least $110 million in Q2 2026, showing steady growth.
Disproves:ARIKAYCE revenue drops below $400 million in 2026. This shows possible market problems.
Why it matters: Progress on INS1148 is crucial for expanding the product pipeline. Delays could hurt future growth.
Confirms one read:There was an announcement of good trial results or a partnership for INS1148.
Confirms the other:There was an announcement of delays or problems in INS1148 development.
Why it matters: If healthcare revenue growth speeds up, it could benefit Insmed's performance.
Confirms:Healthcare revenue growth increases back toward 10% or higher.
Disproves:Healthcare revenue growth keeps slowing down. It is now below 10%.
Why it matters: Results from the CEDAR study will impact the outlook for brensocatib.
Confirms:Good results from the CEDAR study are announced.
Disproves:Negative results or delays in the CEDAR study are reported.
Why it matters: Good results would show that TPIP could be a top treatment for pulmonary arterial hypertension.
Confirms:Data shows big improvements in 6MWD and safety in the PALM-PAH study.
Disproves:Data shows no improvements in 6MWD or safety issues in the PALM-PAH study.
Why it matters: Submitting an IND shows progress in creating new treatments for lung diseases.
Confirms:Announcement of successful IND submission for INS1148 by the end of 2026.
Disproves:No IND submission was announced by the end of 2026. This shows delays in development.
